Loading...
XJPX
7749
Market cap250mUSD
Oct 09, Last price  
2,691.00JPY
1D
-1.61%
1Q
-4.68%
Jan 2017
-41.31%
IPO
-9.55%
Name

Medikit Co Ltd

Chart & performance

D1W1MN
XJPX:7749 chart
P/E
12.96
P/S
1.64
EPS
207.63
Div yield, %
3.47%
Shrs. gr., 5y
-2.92%
Rev. gr., 5y
4.25%
Revenues
23.78b
+5.45%
11,574,000,00011,926,000,00012,331,000,00012,967,980,00013,779,380,00014,126,939,00013,990,802,00014,529,363,00014,850,163,00015,722,076,00016,850,581,99917,445,214,00018,501,799,00019,893,197,00019,312,663,00020,130,697,00021,607,233,00021,850,545,00022,553,238,00023,781,456,000
Net income
3.01b
-0.25%
1,809,000,0001,697,000,0001,608,000,0001,758,919,0002,110,804,9992,032,759,0001,830,482,0001,946,399,0002,184,414,0002,307,512,0002,295,818,0002,465,174,0002,576,365,0002,887,989,0002,659,007,0002,993,017,0002,864,589,0003,069,466,0003,013,544,0003,006,084,000
CFO
4.74b
+32.93%
1,607,000,0002,034,000,0002,347,000,0002,730,977,0002,812,295,0002,461,607,0002,528,504,0002,996,574,0002,583,656,0003,288,259,0002,951,472,0003,116,467,0003,800,265,0003,553,751,0003,640,398,0003,186,041,0004,481,595,0004,835,298,0003,562,500,0004,735,607,000
Dividend
Mar 31, 202750 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in Tokyo, Japan, in 1973, Medikit Co.,Ltd. specializes in the development, manufacturing, and global distribution of advanced medical devices for vascular access. Their comprehensive product portfolio encompasses various intravenous (IV) catheters, such as Supercath 5, Supercath Z3V, and Supercath Ztu-V. They further provide solutions for hemodialysis, including Supercath PRO, Supercath NEO, and Supercath Clampcath, alongside interventional products like Supersheath and Mongoose. These critical medical instruments find application in diverse healthcare settings, notably in anesthesiology departments, operating theaters, intensive care units (ICUs), and within both dialysis and cardiology facilities. Medikit Co.,Ltd. expands its market reach by leveraging a network of distributors, serving approximately 20 countries and territories throughout the European Union and the Americas.

Key people

Takashi Nakajima
Vice President, President of Subsidiary, Director · since 2021
Takashi Hodatsu
Executive Officer, Director of West Japan Sales · since 2024
Hajime Tobita
Executive Officer, Director of East Japan Sales, Director Incharge of Dialysis Business of Marketing Unit · since 2024
Kazuaki Yokoyama
Executive Officer, Director of Marketing · since 2023
Sadayuki Senoh
Executive Officer, Director of General Affairs · since 2023
Hiroshi Horinouchi
Director · since 2015
Yoji Kageyama
President, Representative Director · since 2021
Fumihiro Nakajima
Director · since 2019
Toshiyuki Irie
Independent Director · since 2025
Atsuko Otaki
Independent Director · since 2021
Yasuyuki Yoshida
Independent Director · since 2015
IPO date
Jun 01, 2005
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT